Inside USP: A Holistic Approach to Supply-Chain Integrity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside USP: A Holistic Approach to Supply-Chain Integrity
US Pharmacopeia documents best supply-chain practices and seeks broad input on proposal.


Pharmaceutical Technology
Volume 36, Issue 3, pp. 80-82

Listen to USP officials speak about supply chain integrity as part of a video series. Go to PharmTech.com/PharmTechTV and click on the "USP" tab.

One of the most daunting challenges facing pharmaceutical companies is securing the long and complex supply chains that are typical in today's global industry. From the sourcing of raw materials to final delivery to the pharmacy, practitioner or patient, the number of nodes in the global supply chain for a medicine is astounding, with each link presenting an opportunity for the insertion of risk or harm. Although most companies have highly sophisticated, multifaceted approaches to addressing this challenge, approaches vary.

In addition, there can be huge differences in approach not only between large and small or medium pharmaceutical manufacturers, but also among raw-materials suppliers, logistics providers, and the plethora of other companies involved in the production, distribution, and delivery of medicines to patients.

For example, many companies involved in the chain do not handle pharmaceuticals as their primary business. Despite the good work and due diligence that a pharmaceutical company, wholesale distributor, or other supply-chain stakeholder may employ, the effort can be rendered useless at the seemingly smallest breach. Wherever the breach occurs, someone may be there to take advantage. In the pharmaceutical supply chain, therefore, every step is important, and a company truly is only as strong as the weakest link.

To address this issue, the US Pharmacopeia (USP) recently published a proposed set of recommended best practices on supply-chain integrity, for which it is seeking broad input. If followed, these best practices will help ensure that medicines can be traced back to their original manufacturer, are not adulterated or counterfeited, and are transported to their intended destination with quality intact.

The proposal is contained in the draft USPNF General Chapter <1083> "Good Distribution Practices—Supply Chain Integrity," which is published in the March–April Pharmacopeial Forum (PF) [38(2)].

Once in its final form, the general chapter will document what is envisioned to be a universal approach for helping to achieve supply-chain integrity. The general chapter is informational (i.e., nonmandatory), but USP hopes that the chapter can be a resource for companies that need to be brought up to speed on supply-chain issues and that it can serve as mechanism for building consensus across different industries.

Scope of the USP supply-chain chapter

The USP Packaging, Storage and Distribution Expert Committee, which is responsible for the new general chapter, has been interested in this topic for several years and sees the new proposal as one of an eventual suite of distribution chapters, following on the widely used General Chapter <1079> "Good Storage and Shipping Practices." Supply-chain integrity—which involves minimizing risks that arise anywhere along the supply chain—may be too broad for just one general chapter, however. That is one of the key questions USP has for industry and other stakeholders as it asks for feedback on the new chapter's contents.

USP expects the general chapter to evolve significantly from its draft, and hopes the public vetting will result in a strong final product that will be valuable to all relevant parties, including manufacturers; transportation companies involved in automobile, truck, rail, sea and air services; third-party logistics providers, freight forwarders and consolidators; brokers, importers and exporters; packaging and repackaging operations; wholesalers and distributors; retail, mail-order, hospital, nursing home and other pharmacies; and mail distributors, including the US Postal Service and other expedited shipping services.

The general chapter <1083> provides recommendations on how to minimize risk in international supply chains through effective partnerships and manufacturing quality systems. As it is written, the chapter covers four main areas:

  • Importation, which details three primary initiatives importers should undertake to help prevent and detect potential risks (i.e., supply-chain risk management, development of effective supplier partnerships, and building a supply-chain quality system).
  • Counterfeit Drugs and Medical Devices, which documents types of counterfeit drugs, medical consequences, and distribution and extent of counterfeit drugs and devices.
  • Best Practices to Combat Counterfeit Drugs and Medical Devices, which covers packaging technologies (e.g., tamper-evident designs, authentication technologies and serialization); drug pedigrees; machine-readable data carriers (e.g., two-dimensional [2D] barcodes and radiofrequency identification [RFID] tags); repackaging guidance; information retention and security; best anticounterfeiting practices, and more.
  • Diversion and Theft, which addresses factors that raise the risk of theft of drug products and components; security systems, devices, and procedures that should be implemented to reduce risk; and critical information to be gathered after a theft.

The practices included in the general chapter are top-level, and are purposefully nonprescriptive so as not to box companies in to one way of doing something. The general chapter intends to set a framework; companies can use the best approaches for them within that framework. When discussing track-and-trace technology, for instance, USP points to the two most widely recognized options: RFID and 2D barcodes. It is not, however, USP's role to decide on the actual technology to be implemented.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here